# Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure

> **NCT01961726** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Juventas Therapeutics, Inc.** · enrollment: 72 (estimated)

## Conditions studied

- Ischemic Heart Failure

## Interventions

- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** 30 mg dose of JVS-100
- **BIOLOGICAL:** 45 mg dose of JVS-100

## Key facts

- **NCT ID:** NCT01961726
- **Lead sponsor:** Juventas Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-10
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2014-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01961726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01961726, "Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT01961726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*